Status
Conditions
Treatments
About
The aim of this pilot study is to provide an assessment of safety and feasibility of early minimally invasive image guided endoscopic hematoma evacuation (within 24 hours of symptom onset) in patients suffering from intracerebral haemorrhage (ICH).
Full description
Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the is the second most common form of stroke. The aim of this single centre, single arm pilot study is to provide an assessment of safety and feasibility of early minimally invasive image guided endoscopic hematoma evacuation (within 24 hours of symptom onset) in patients suffering from intracerebral haemorrhage (ICH).
Furthermore this study contributes to the understanding of secondary neuronal damage involved in ICH through the measurement of biomarkers for neuronal damage and their response to early hematoma evacuation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
No relevant disability prior to ICH (mRS 0-1 prior to ICH)
Primary supratentorial deep or superficial intraparenchymal ICH of volume ≥ 20 mL < 100 mL (measured using formula) demonstrated on CT or MRI, with or without a 2 component of intraventricular haemorrhage
CT/MRI demonstrates ICH stability (< 5 mL growth) at 6 hours after the admission scan if surgery is performed >6 hours after admission CT
NIHSS ≥ 8 OR if a patient with a NIHSS<8 presents with at least one of the following deficits:
Presenting GCS 5 - 15
Endoscopic haematoma evacuation can be initiated within 24 hours of symptom onset
Systolic blood pressure can be controlled at <160 mmHg
Exclusion criteria
Imaging:
Coagulation Issues:
Presenting GCS 3 or 4
Requirement for emergent surgical decompression or uncontrolled ICP after EVD
Unable to obtain consent from patient or appropriate surrogate (for patients without competence)
Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (woman of child-bearing potential must have a negative history of current pregnancy prior to the study procedure)
Evidence of active infection (indicated by fever ≥38°C) at the time of study inclusion
Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days
Based on physician's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule
Active drug or alcohol use or dependence
Primary purpose
Allocation
Interventional model
Masking
11 participants in 1 patient group
Loading...
Central trial contact
Jehuda Soleman, PD Dr. med.; Leo Bonati, Prof. Dr. med.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal